Cellular Reprogramming for Longevity

Cellular reprogramming uses Yamanaka factors or engineered variants to partially reset a cell's epigenetic state to a younger configuration without fully dedifferentiating it into a stem cell. Altos Labs, funded with $3 billion from Jeff Bezos among others, is the largest single bet on reprogramming, with clinical trials rumored for 2026. Retro Biosciences demonstrated effective reprogramming factors beyond natural Yamanaka factors. Life Biosciences showed liver and eye tissue rejuvenation.

If partial reprogramming works in humans, it could reverse aspects of aging at the cellular level — restoring tissue function, reducing inflammation, and extending healthy lifespan. This isn't incremental life extension but a potential paradigm shift in how we think about aging as a treatable condition rather than an inevitable decline.

The US leads in longevity biotech with over $5 billion in combined funding across reprogramming companies. The XPRIZE Healthspan competition awarded $10 million each to 10 finalists for one-year clinical trials. The strategic implications are profound: a society that can extend productive healthspan by even a decade would see enormous economic benefits, but also face unprecedented challenges in pension systems, workforce dynamics, and healthcare infrastructure.